Powe et al studied the implications of using YY1 and AP-2 as therapeutic targets in breast cancer and found that AP-2 alpha/beta correlated significantly with YY1 and could be used as important markers for the prognosis of cancer [50]. This evidence concerns the gene YY1 and breast cancer.